ArticleComputational and structural biotechnology journal2025
Subtypes detection of papillary thyroid cancer from methylation assay via Deep Neural Network.
Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DNA methylation and machine learning: challenges and perspective toward enhanced clinical diagnostics.Clinical epigenetics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: In recent years, DNA methylation-tumor classification based on artificial intelligence algorithms has led to a notable improvement in diagnostic accuracy compared to traditional machine learning methods. In cancer, the methylation pattern likely reflects both the cell of origin and somatically acquired DNA methylation changes, making this epigenetic modification an ideal tool for tumor classification. We propose an in-depth method based on the Convolutional Neural Network for the DNA methylation-based classification of papillary thyroid carcinoma (PTC) and its follicular (fvPTC) and classical (cvPTC) subtypes. Methods: To address this issue, we first performed a pan-cancer analysis to train a convolutional 1-D Neural Network (CNN) using supervised learning. Then, we evaluated the robustness of the net on an independent PTC dataset and assessed its ability to classify normal (N=56) versus tumor (N=461) samples and fvPTC (N=102) versus cvPTC (N=359). We then compared its performance with 4 machine learning models (logistic regression with elastic net penalty, quadratic discriminant analysis, support vector classifier with RBF kernel, and random forest). Results: By using RELU activation function and leaving out liquid tumors, our results show a remarkable performance of the neural network in classifying cancer and normal samples when applied to pan-cancer data (Validation AUC = 0.9903 and Validation Loss = 0.112). When applied to the thyroid independent dataset, the proposed Neural Net architecture successfully discriminates tumor versus normal samples (AUC = 0.91 +/- 0.05) and follicular versus classical PTC subtypes (AUC = 0.80 +/- 0.05), outperforming traditional machine learning algorithms. Conclusions: In conclusion, the study highlights the effectiveness of CNNs in the methylation based classification of thyroid tumors and their subtypes, demonstrating its ability to capture subtle epigenetic differences with minimal preprocessing.This versatility makes the model adaptable for classifying other tumor types. Also, the findings emphasize the potential relevance of AI algorithms in addressing complex diagnostic challenges and supporting clinical decisions.This research lays the foundation for developing robust and generalizable models that can advance precision oncology in cancer diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.